- Home
- ADXN vs LCFY Comparison
ADXN vs LCFY Comparison
Compare ADXN & LCFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADXN
- LCFY
- Stock Information
- Founded
- ADXN 2002
- LCFY 2009
- Country
- ADXN Switzerland
- LCFY Australia
- Employees
- ADXN N/A
- LCFY N/A
- Industry
- ADXN Biotechnology: Pharmaceutical Preparations
- LCFY
- Sector
- ADXN Health Care
- LCFY
- Exchange
- ADXN Nasdaq
- LCFY Nasdaq
- Market Cap
- ADXN 8.0M
- LCFY 7.3M
- IPO Year
- ADXN N/A
- LCFY 2022
- Fundamental
- Price
- ADXN $7.97
- LCFY $8.50
- Analyst Decision
- ADXN Strong Buy
- LCFY
- Analyst Count
- ADXN 1
- LCFY 0
- Target Price
- ADXN $30.00
- LCFY N/A
- AVG Volume (30 Days)
- ADXN 25.1K
- LCFY 23.2K
- Earning Date
- ADXN 11-22-2024
- LCFY 11-12-2024
- Dividend Yield
- ADXN N/A
- LCFY N/A
- EPS Growth
- ADXN N/A
- LCFY N/A
- EPS
- ADXN 0.06
- LCFY N/A
- Revenue
- ADXN $701,260.00
- LCFY $2,668,385.00
- Revenue This Year
- ADXN N/A
- LCFY N/A
- Revenue Next Year
- ADXN N/A
- LCFY N/A
- P/E Ratio
- ADXN $1.03
- LCFY N/A
- Revenue Growth
- ADXN N/A
- LCFY N/A
- 52 Week Low
- ADXN $6.45
- LCFY $2.20
- 52 Week High
- ADXN $27.90
- LCFY $11.23
- Technical
- Relative Strength Index (RSI)
- ADXN 50.40
- LCFY 60.26
- Support Level
- ADXN $7.28
- LCFY $6.78
- Resistance Level
- ADXN $8.36
- LCFY $10.54
- Average True Range (ATR)
- ADXN 0.74
- LCFY 0.68
- MACD
- ADXN 0.05
- LCFY 0.09
- Stochastic Oscillator
- ADXN 50.26
- LCFY 48.87
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.
About LCFY Locafy Limited
Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has three operating segments: the Publishing segment, the Reseller segment, and the Channel sales segment. It derives a majority of its revenue from Australia and New Zealand.